Pfizer’s abrocitinib scores another phase III win in atopic dermatitis
admin 12th November 2020 Uncategorised 0JADE REGIMEN study investigated JAK1 inhibitor in moderate to severe atopic dermatitis
More: Pfizer’s abrocitinib scores another phase III win in atopic dermatitis
Source: News